In fact, the transcriptional levels of ESR1 are clearly decreased in relapsed tumor lesions when compared to primary tumors in tamoxifen-treated ER+ breast cancers, which suggests a possible transcriptional inhibition of ESR1 during acquired resistance to tamoxifen [371]. Here, ESR1 is linked to breast cancer.